CSIMarket



Worst Performing Stocks In Major Pharmaceutical Preparations Industry During This Month Of July



 1 Day   Week  Current Month of July  30 Days 
Current Quarter Q3 of 2024  90 Days    Ytd    12 Months 
 

Shares increased by 2.39% on average, in Major Pharmaceutical Preparations Industry during this month of July.

Here are the Worst performing stocks in Major Pharmaceutical Preparations Industry.




BMY

$40.15

$-1.1500 -2.78%
This Month of July


BMY

$40.15

$-1.1500 -2.78%



Bristol myers Squibb Company

Bristol Myers Squibb Company stock declined -2.78% during this month of July.


Bristol Myers Squibb Company is a pharmaceutical firm that operates on a research and development-driven business model, focused on discovering, developing, and delivering innovative medicines to treat various diseases. The company collaborates with academic institutions, government organizations, and other pharmaceutical companies to advance their portfolio of therapeutics and improve patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 81,192.980 mill. $ 45,534.000 mill. $ -6,135.000 mill. 2,022 mill. - Y/Y 4.66 %
Market Cap. Revenues TTM Net Income TTM

$ 81,192.980 mill.


$ 45,534.000 mill.


$ -6,135.000 mill.

Employees Shares Outstanding P/E

32,200


2,022 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 4.66 %


MRQ Y/Y - %



ABBV

$168.03

$-2.3400 -1.37%
This Month of July


ABBV

$168.03

$-2.3400 -1.37%



Abbvie Inc

Abbvie Inc stock dropped -1.37% during this month of July.


Abbvie Inc operates primarily as a global biopharmaceutical company. Its business model centers around researching, developing, manufacturing, and commercializing advanced therapies and medications focusing on critical areas like immunology, oncology, neuroscience, virology, and more. By leveraging its expertise and capabilities, Abbvie aims to improve patient outcomes, address unmet medical needs, and provide value to its stakeholders in the healthcare industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 297,917.190 mill. $ 54,403.000 mill. $ 6,004.000 mill. 1,773 mill. 49.79 Y/Y 0.70 %
Market Cap. Revenues TTM Net Income TTM

$ 297,917.190 mill.


$ 54,403.000 mill.


$ 6,004.000 mill.

Employees Shares Outstanding P/E

50,000


1,773 mill.


49.79

Revenue Growth Income Growth

MRQ Y/Y 0.70 %


MRQ Y/Y 469.29 %



ABT

$102.96

$-0.2400 -0.23%
This Month of July


ABT

$102.96

$-0.2400 -0.23%



Abbott Laboratories

Abbott Laboratories shares dropped -0.23% during this month of July.


Abbott Laboratories operates as a diversified healthcare company with a broad portfolio of products. Their business model is centered around developing and manufacturing various health-related products, including pharmaceuticals, medical devices, nutritional products, and diagnostic technologies. They aim to serve a wide range of healthcare sectors globally by providing innovative solutions that improve the quality of patients* lives.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 180,144.170 mill. $ 40,326.000 mill. $ 5,630.000 mill. 1,750 mill. 32.01 Y/Y 2.23 %
Market Cap. Revenues TTM Net Income TTM

$ 180,144.170 mill.


$ 40,326.000 mill.


$ 5,630.000 mill.

Employees Shares Outstanding P/E

113,000


1,750 mill.


32.01

Revenue Growth Income Growth

MRQ Y/Y 2.23 %


MRQ Y/Y -7.06 %



MRK

$128.12

$0.2200 0.17%
This Month of July


MRK

$128.12

$0.2200 0.17%



Merck and Co Inc

Merck And Co Inc stock improved 0.17% during this month of July.


Merck and Co Inc operates primarily as a research-intensive pharmaceutical company, engaging in the development, manufacturing, and marketing of prescription drugs and vaccines worldwide. The company focuses on discovering innovative solutions to address unmet medical needs across various therapeutic areas, collaborating with academic institutions and conducting clinical trials to evaluate the efficacy and safety of their products. Merck and Co Inc also holds a strong commitment to the well-being of patients and aims to contribute to global healthcare by delivering high-quality, affordable medications.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 326,260.663 mill. $ 61,403.000 mill. $ 2,319.000 mill. 2,547 mill. 135.83 Y/Y 8.89 %
Market Cap. Revenues TTM Net Income TTM

$ 326,260.663 mill.


$ 61,403.000 mill.


$ 2,319.000 mill.

Employees Shares Outstanding P/E

68,000


2,547 mill.


135.83

Revenue Growth Income Growth

MRQ Y/Y 8.89 %


MRQ Y/Y 68.74 %



JNJ

$149.24

$2.8000 1.91%
This Month of July


JNJ

$149.24

$2.8000 1.91%



Johnson and Johnson

Johnson And Johnson shares went up 1.91% during this month of July.


Johnson & Johnson operates as a multinational healthcare company with a diversified model. They develop, manufacture, and sell a broad range of pharmaceutical, medical devices, and consumer goods. Their business is focused on improving the health and well-being of people worldwide through innovation, research, and strategic acquisitions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 362,668.124 mill. $ 89,659.000 mill. $ 38,476.000 mill. 2,430 mill. 9.82 Y/Y -13.59 %
Market Cap. Revenues TTM Net Income TTM

$ 362,668.124 mill.


$ 89,659.000 mill.


$ 38,476.000 mill.

Employees Shares Outstanding P/E

141,700


2,430 mill.


9.82

Revenue Growth Income Growth

MRQ Y/Y -13.59 %


MRQ Y/Y - %



OGN

$20.73

$0.4200 2.07%
This Month of July


OGN

$20.73

$0.4200 2.07%



Organon and Co

Organon And Co shares increased 2.07% during this month of July.


Organon and Co*s business model revolves around developing and manufacturing pharmaceutical products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5,355.844 mill. $ 6,347.000 mill. $ 1,047.000 mill. 258 mill. 5.08 Y/Y 5.46 %
Market Cap. Revenues TTM Net Income TTM

$ 5,355.844 mill.


$ 6,347.000 mill.


$ 1,047.000 mill.

Employees Shares Outstanding P/E

9,300


258 mill.


5.08

Revenue Growth Income Growth

MRQ Y/Y 5.46 %


MRQ Y/Y 13.56 %



CTLT

$57.84

$1.6800 2.99%
This Month of July


CTLT

$57.84

$1.6800 2.99%



Catalent Inc

Catalent Inc stock went up 2.99% during this month of July.


Catalent Inc*s business model is based on providing advanced delivery technologies and development solutions for pharmaceutical, biotechnology, and consumer health companies. They offer a range of services including drug development, manufacturing, packaging, and supply chain capabilities. Their focus is on helping their clients bring innovative and life-saving products to market efficiently and effectively.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 10,431.857 mill. $ 4,135.000 mill. $ -1,176.000 mill. 180 mill. - Y/Y 3.57 %
Market Cap. Revenues TTM Net Income TTM

$ 10,431.857 mill.


$ 4,135.000 mill.


$ -1,176.000 mill.

Employees Shares Outstanding P/E

19,000


180 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 3.57 %


MRQ Y/Y - %



PFE

$29.1

$0.8800 3.12%
This Month of July


PFE

$29.1

$0.8800 3.12%



Pfizer Inc

Pfizer Inc stock improved 3.12% during this month of July.


Pfizer Inc operates as a global pharmaceutical company, focused on discovering, developing, manufacturing, and marketing innovative medicines. Its business model revolves around investing in research and development to create a diverse portfolio of therapies across various therapeutic areas. Leveraging its scale, Pfizer aims to commercialize these products globally and drive growth through strategic alliances and collaborations with other industry players.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 165,782.700 mill. $ 55,093.000 mill. $ -275.000 mill. 5,697 mill. - Y/Y -18.61 %
Market Cap. Revenues TTM Net Income TTM

$ 165,782.700 mill.


$ 55,093.000 mill.


$ -275.000 mill.

Employees Shares Outstanding P/E

79,000


5,697 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -18.61 %


MRQ Y/Y -43.79 %



LLY

$950.46

$36.0900 3.95%
This Month of July


LLY

$950.46

$36.0900 3.95%



Eli Lilly And Company

Eli Lilly And Company stock improved 3.95% during this month of July.


Eli Lilly and Company operates as a pharmaceutical company, primarily focused on researching, developing, manufacturing, and marketing prescription drugs across various therapeutic areas.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 859,025.748 mill. $ 35,932.100 mill. $ 6,138.400 mill. 904 mill. 139.90 Y/Y 25.98 %
Market Cap. Revenues TTM Net Income TTM

$ 859,025.748 mill.


$ 35,932.100 mill.


$ 6,138.400 mill.

Employees Shares Outstanding P/E

35,000


904 mill.


139.90

Revenue Growth Income Growth

MRQ Y/Y 25.98 %


MRQ Y/Y 66.77 %




 1 Day   Week  Current Month of July  30 Days 
Current Quarter Q3 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com